Coloplast A/S
Coloplast A/S (CLPBY) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
clpby · pe ratio · data through Sep 30, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Coloplast A/S (CLPBY) measures how much investors pay for each dollar of the company's trailing earnings. CLPBY's current PE ratio of 41.06x is calculated by dividing its stock price of $5.94 by its TTM earnings per share of $9.34. +9.5% elevated vs 5Y avg 37.5x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-09-30
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 20 fiscal years · Front-end computedMinQ1 · 25%43.7x
MedianQ3 · 75%223.4x
Max
At 41.06x, CLPBY's current P/E is within its average historical range over the past 20 fiscal years.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Devices · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Coloplast A/SYou CLPBY | $13.4B | 41.06x | -6.5% | $9.34 |
 Astellas Pharma Inc. ALPMY | $24.2B | 14.92x | -66.0% | $172.58 |
 Orion Oyj ORINY | $22.9B | 36.71x | -16.4% | $0.85 |
 Straumann Holding AG SAUHF | $19.0B | 41.68x | -5.1% | $2.24 |
 Straumann Holding AG SAUHY | $18.9B | 43.20x | -1.7% | $0.21 |
 Sino Biopharmaceutical Limited SBHMY | $11.6B | 50.31x | +14.5% | $2.53 |
 Sartorius Stedim Biotech S.A. SDMHF | $20.0B | 76.73x | +74.7% | $2.73 |
Industry Average 6 peers with valid PE | — | 43.92x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-09-30Latest FY2025 | 35.71x | $1.52 | -8.5% | |
2024-09-30 FY2024 | 39.01x | $2.25 | +16.2% | |
2023-09-30 FY2023 | 33.57x | $2.22 | -3.9% | |
2022-09-30 FY2022 | 34.94x | $2.21 | -21.2% | |
2021-09-30 FY2021 | 44.34x | $2.27 | -12.6% | |
2020-09-30 FY2020 | 50.71x | $1.97 | +12.2% | |
2019-09-30 FY2019 | 45.21x | $1.82 | +23.9% | |
2018-09-30 FY2018 | 36.50x | $1.81 | +27.7% | |
2017-09-30 FY2017 | 28.58x | $1.79 | -17.7% | |
2016-09-30 FY2016 | 34.71x | $1.48 | -68.8% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Coloplast A/S (CLPBY) measures how much investors pay for each dollar of the company's trailing earnings. CLPBY's current PE ratio of 41.06x is calculated by dividing its stock price of $5.94 by its TTM earnings per share of $9.34.
Frequently asked questions
CLPBY pe ratio · 6 questionsCLPBY's current PE ratio is 41.06x as of 2026-06-09, based on a stock price of $5.94 and TTM EPS of $9.34. Data sourced from Financial Modeling Prep via CLPBY's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Coloplast A/S SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09